Elsevier

Clinical Lung Cancer

Volume 3, Issue 1, August 2001, Pages 37-41
Clinical Lung Cancer

Original Contribution
Photodynamic Therapy for Patients with Advanced Non–Small-Cell Carcinoma of the Lung

https://doi.org/10.3816/CLC.2001.n.016Get rights and content

Abstract

Patients with advanced non–small-cell lung carcinoma (NSCLC) have poor prognoses and experience negative sequelae of disease. Patients often suffer from dyspnea and/or hemoptysis, with overall pulmonary compromise. Patients with advanced, inoperable disease have limited options for treatment. This study summarizes our early experience and findings using photodynamic therapy (PDT) as an effective modality in the palliation of hemoptysis, dyspnea, and physical airway obstruction in cases of inoperable lung cancer. A retrospective review was conducted for the first 10 patients diagnosed with stage III/IV obstructive NSCLC who underwent PDT at our institution. Endobronchial lesions were identified by bronchoscopy. Treatments were initiated 48 hours after intravenous injection of 2 mg/kg of the photosensitizing agent porfimer sodium (Photofrin, QLT PhotoTherapeutics, Vancouver, BC). The porfimer sodium was then activated by illumination with a 630 nm wavelength light using a Coherent argon ion laser through a flexible bronchoscope. Repeated bronchoscopies were performed 1-3 days following initial PDT for evaluation and airway debridement. In 8 cases, a second treatment of PDT was administered within 72 hours of the first injection. One patient received a third treatment several months later. Three patients also received endobronchial stents after PDT. Overall, all 10 patients responded to PDT. Physical airway obstruction was reduced in all patients, with a noted improvement in bronchoscopic luminal diameter. Acute hemoptysis resolved in all 7 symptomatic patients. Median survival was 5.5 months post-PDT, while median survival postdiagnosis was 10.5 months. Three patients are alive at the time of this review at 5-21 months following therapy. Patients with unresectable late-stage NSCLC have few options for treatment. Our early experience with PDT indicates effective relief of hemoptysis, dyspnea, and airway obstruction and improves their quality of life.

References (19)

There are more references available in the full text version of this article.

Cited by (28)

  • Photodynamic therapy for lung cancer and malignant pleural mesothelioma

    2014, Seminars in Oncology
    Citation Excerpt :

    PDT also can serve as a management tool for hemoptysis by causing thrombosis and controlling small vessel bleeding.24 In fact, resolution of acute bleeding was achieved in 70% of patients treated at the University of California, Irvine with stage III–IV obstructive inoperable NSCLC with hemoptysis, dyspnea, and airway obstruction.25 Similar excellent control of hemoptysis was achieved with PDT in a prospective study in Austria.26

  • Endobronchial Ablative Therapies

    2013, Clinics in Chest Medicine
    Citation Excerpt :

    The photosensitization agent is taken up by actively metabolizing cells and to a higher degree by malignant tissues.22,23 A standard bronchoscope is then used to survey the airway and to advance the light probe into position.22,23 Once in position, the light probe is activated and emits light at a specific frequency to activate the photosensitizing agent.22,23

  • Surgical and Endoscopic Palliation of Advanced Lung Cancer

    2011, Surgical Oncology Clinics of North America
    Citation Excerpt :

    Repeat treatment can also be performed after debridement but needs to be performed within the prescribed time (within 7 days of Photofrin injection) to achieve additional tumoricidal effect. Several studies have confirmed the efficacy and safety of PDT procedures for cancer, and, in those with advanced-stage cancer and endoluminal bronchial obstruction, PDT is capable of providing significant palliative improvement and may have a more durable benefit than mechanical debridement or laser resection because of its wider radial effect of tumor necrosis, which may delay tumor regrowth and obstruction.8 In many cases of NSCLC, patients with inoperable cancer are referred for PDT following recurrence of tumor after chemotherapy/radiotherapy.9

  • Photodynamic activity of aloe-emodin induces resensitization of lung cancer cells to anoikis

    2010, European Journal of Pharmacology
    Citation Excerpt :

    Photodynamic therapy is an effective therapy for local malignant tumors and involves a tumor-localizing photosensitizing agent, light and molecular oxygen (Castano et al., 2006; Morton et al., 2002). Recently, photodynamic therapy has been a treatment option for lung cancer that involves the administration of a photosensitizing agent and fiberoptic bronchoscope, which was used to deliver light to tumor tissue that has retained the agent (Jones et al., 2001; McCaughan, 1999). Aloe-emodin is an anthraquinone derivative similar to hypericin in structure, the third generation photosensitizer.

View all citing articles on Scopus
View full text